Targeted delivery of melittin to cancer cells by AS1411 anti-nucleolin aptamer

References

• Shapira A, Livney YD, Broxterman HJ, et al. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat. 2011;14:150–163.
   PubMed Web of Science ®Google Scholar
• Alves NJ, Kiziltepe T, Bilgicer B. Oriented surface immobilization of antibodies at the conserved nucleotide binding site for enhanced antigen detection. Langmuir. 2012;28:9640–9648.
   PubMed Web of Science ®Google Scholar
• Estanqueiro M, Amaral MH, Conceicao J, et al. Nanotechnological carriers for cancer chemotherapy: the state of the art. Coll Surf B Biointerfaces. 2015;126:631–48.
   PubMed Web of Science ®Google Scholar
• Gotay CC. Cancer prevention: major initiatives and looking into the future. Expert Rev Pharmacoecon Outcomes Res. 2010;10:143–154.
   PubMed Web of Science ®Google Scholar
• Gajski G, Garaj-Vrhovac V. Melittin: a lytic peptide with anticancer properties. Env Toxicol Pharmacol. 2013;36:697–705.
   PubMed Web of Science ®Google Scholar
• Raghuraman H, Chattopadhyay A. Melittin: a membrane-active peptide with diverse functions. Biosci Rep. 2007;27:189–223.
   PubMed Web of Science ®Google Scholar
• Leuschner C, Hansel W. Membrane disrupting lytic peptides for cancer treatments. Curr Pharm Des. 2004;10:2299–2310.
   PubMed Web of Science ®Google Scholar
• Soman NR, Baldwin SL, Hu G, et al. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest. 2009;119:2830–2842.
   PubMed Web of Science ®Google Scholar
• Park MH, Choi MS, Kwak DH, et al. Anti-cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF-kappaB. Prostate. 2011;71:801–812.
   PubMed Web of Science ®Google Scholar
• Park JH, Jeong YJ, Park KK, et al. Melittin suppresses PMA-induced tumor cell invasion by inhibiting NF-kappaB and AP-1-dependent MMP-9 expression. Mol Cells. 2010;29:209–215.
   PubMed Web of Science ®Google Scholar
• Liu S, Yu M, He Y, et al. Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway. Hepatology. 2008;47:1964–1973.
   PubMed Web of Science ®Google Scholar
• Zhu HG, Tayeh I, Israel L, et al. Different susceptibility of lung cell lines to inhibitors of tumor promotion and inducers of differentiation. J Biol Regul Homeost Agents. 1991;5:52–58.
   PubMed Web of Science ®Google Scholar
• Sundaram P, Kurniawan H, Byrne ME, et al. Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci. 2013;48:259–271.
   PubMed Web of Science ®Google Scholar
• Zhu J, Huang H, Dong S, et al. Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges. Theranostics. 2014;4:931–944.
   PubMed Web of Science ®Google Scholar
• Stoltenburg R, Reinemann C, Strehlitz B. SELEX—a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Engin. 2007;24:381–403.
   PubMedGoogle Scholar
• Pei X, Zhang J, Liu J. Clinical applications of nucleic acid aptamers in cancer. Mol Clin Oncol. 2014;2:341–348.
   PubMedGoogle Scholar
• Shangguan D, Li Y, Tang Z, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA. 2006;103:11838–11843.
   PubMed Web of Science ®Google Scholar
• Reyes-Reyes EM, Teng Y, Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res. 2010;70:8617–8629.
   PubMed Web of Science ®Google Scholar
• Bates PJ, Laber DA, Miller DM, et al. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol. 2009;86:151–164.
   PubMed Web of Science ®Google Scholar
• Ginisty H, Sicard H, Roger B, et al. Structure and functions of nucleolin. J Cell Sci. 1999;112:761–772.
   PubMed Web of Science ®Google Scholar
• Rizzieri D, Stockerl-Goldstein K, Wei A, et al. Long-term outcomes of responders in a randomized, controlled phase II trial of aptamer AS1411 in AML. J Clin Oncol. 2010;28:6557.
   Google Scholar
• Mongelard F, Bouvet P. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr Opin Mol Ther. 2010;12:107–114.
   PubMed Web of Science ®Google Scholar
• Alibolandi M, Abnous K, Ramezani M, et al. Synthesis of AS1411-aptamer-conjugated CdTe quantum dots with high fluorescence strength for probe labeling tumor cells. J Fluoresc. 2014;24:1519–1529.
   PubMed Web of Science ®Google Scholar
• Chevallet M, Luche S, Rabilloud T. Silver staining of proteins in polyacrylamide gels. Nat Protoc. 2006;1:1852–1858.
   PubMed Web of Science ®Google Scholar
• Guo Y-q, Sun H-y, Chan C-o, et al. Centipeda minima (Ebushicao) extract inhibits PI3K-Akt-mTOR signaling in nasopharyngeal carcinoma CNE-1 cells. Chinese Med. 2015;10:1–9.
   PubMed Web of Science ®Google Scholar
• Jiang F, Liu B, Lu J, et al. Progress and challenges in developing aptamer-functionalized targeted drug delivery systems. Int J Mol Sci. 2015;16:23784–23822.
   PubMed Web of Science ®Google Scholar
• Pan H, Soman NR, Schlesinger PH, et al. Cytolytic peptide nanoparticles (‘NanoBees’) for cancer therapy. WIREs Nanomed Nanobiotechnol. 2011;3:318–327.
   PubMed Web of Science ®Google Scholar
• Alibolandi M, Ramezani M, Sadeghi F, et al. Epithelial cell adhesion molecule aptamer conjugated PEG–PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro. Int J Pharm. 2015;479:241–251.
   PubMed Web of Science ®Google Scholar
• Taghdisi SM, Abnous K, Mosaffa F, et al. Targeted delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer. J Drug Target. 2010;18:277–281.
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Salmasi Z, Hashemi M, et al. Single-walled carbon nanotubes functionalized with aptamer and piperazine–polyethylenimine derivative for targeted siRNA delivery into breast cancer cells. Int J Pharm. 2015;485:50–60.
   PubMed Web of Science ®Google Scholar
• Soundararajan S, Wang L, Sridharan V, et al. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Mol Pharmacol. 2009;76:984–991.
   PubMed Web of Science ®Google Scholar
• Li X, Yu Y, Ji Q, et al. Targeted delivery of anticancer drugs by aptamer AS1411 mediated Pluronic F127/cyclodextrin-linked polymer composite micelles. Nanomed Nanotech Biol Med. 2015;11:175–184.
   PubMed Web of Science ®Google Scholar
• Yang L, Harroun TA, Weiss TM, et al. Barrel-stave model or toroidal model? A case study on melittin pores. Biophys J. 2001;81:1475–1485.
   PubMed Web of Science ®Google Scholar
• Lee M-T, Chen F-Y, Huang HW. Energetics of pore formation induced by membrane active peptides. Biochemistry. 2004;43:3590–3599.
   PubMed Web of Science ®Google Scholar
• Habermann E, Zeuner G. Comparative studies of native and synthetic melittins. Naunyn-Schmiedebergs Arch Pharmak. 1971;270:1–9.
   PubMedGoogle Scholar
• Moon D-O, Park S-Y, Choi YH, et al. Melittin induces Bcl-2 and caspase-3-dependent apoptosis through downregulation of Akt phosphorylation in human leukemic U937 cells. Toxicon. 2008;51:112–120.
   PubMed Web of Science ®Google Scholar
• Jo M, Park MH, Kollipara PS, et al. Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathway. Toxicol Appl Pharmacol. 2012;258:72–81.
   PubMed Web of Science ®Google Scholar